| Literature DB >> 29460207 |
Andrzej Miskiewicz1, Paweł Kowalczyk2, Sanaa Mahdi Oraibi3, Krystyna Cybulska3, Anna Misiewicz4.
Abstract
This article describes methods of treatment for avian zoonoses, modern antibiotic therapy and drug resistance of selected pathogens, which pose a threat to the population's health. A tabular form has been used to present the current data from the European Union from 2011 to 2017 regarding human morbidity and mortality and the costs incurred by national health systems for the treatment of zoonoses occurring in humans and animals. Moreover, the paper includes descriptions of selected diseases, which indirectly affect birds. Scientists can obtain information regarding the occurrence of particular diseases, their aetiology, epidemiology, incubation period and symptoms caused by dangerous microorganisms and parasites. This information should be of particular interest for people who have frequent contact with birds, such as ornithologists, as well as veterinarians, farm staff, owners of accompanying animals and zoological workers. This paper presents a review used for identification and genetic characterization of bacterial strains isolated from a variety of environmental sources, e.g., bird feathers along with their practical application. We describe the bacterial, viral and fungal serotypes present on avian feathers after the slaughter process. This review also enables us to effectively identify several of the early stages of infectious diseases from heterogeneous avian research material.Entities:
Keywords: Bacterial; Bird diseases; Pathogenic microorganisms; Viral and fungal serotypes
Mesh:
Year: 2018 PMID: 29460207 PMCID: PMC6097735 DOI: 10.1007/s10482-018-1048-2
Source DB: PubMed Journal: Antonie Van Leeuwenhoek ISSN: 0003-6072 Impact factor: 2.271
Summary presentation of E. coli strains including serotype, strain virulence and genetic characteristics
| Serotype | Pathotype | Genotype | Antibiotic resistance | Reference | |
|---|---|---|---|---|---|
| K 12 | HB101 O16 | Commensal | MG1655 | Kanamycin | Blattner et al. ( |
| C2834 | O2 | Enterinvasive | Ampicillin, Chloramphenicol, TSX | Rosario et al. ( | |
| DSM 30083T | O1:K1:H7 | Uninary tract infections | U5/41T | Hydrphobic antibiotic, amingli, aminoglycosides, chloramphenicol | Meier-Kolthoff et al. ( |
| Sakai Lineage I | O157:H7 | Diarrhoea | Β-lactams, aminoglycosides | Hayashi et al. ( | |
| SS17 | O157:H7 | HUS | ycfR | Puromycin, acriflavine | Andrews et al. ( |
| SS52 | O157 | pEAF | Β-lactams, tellurite | Katani et al. ( | |
| TW14359, Lineage II | O157, O26:H11, O103:H2 | HUS |
| Β-lactams, chlorine | Batisson et al. ( |
| EC4115, Lineage II | O157:H7 | EHEC |
| ESBL | Zhang et al. ( |
| EDL933, Lineage I | O157:H7 | EHEC |
| Carbenicillin, ampicillinstreptomycin | Foster et al. ( |
Incidence, hospitalization and mortality confirmed in humans for Salmonellosis and the total for all zoonoses in the European Union countries in 2013 and 2015
| year | Type of zoonoses | Number of confirmed human cases | Percentage of all cases of Salmonellosis among all zoonoses | Hospitalisation reported cases | Reported deaths | Percentage of deaths due to Salmonellosis among all zoonoses | Case fatalitya |
|---|---|---|---|---|---|---|---|
| 2013 | Salmonellosis | 82.694 | NA | 7.841 | 59 | NA | 0.14 |
| Total no of zoonoses | 313.636 | 26.6% | 22.199 | 344 | 17.1% | 0.18 | |
| 2015 | Salmonellosis | 94.625 | NA | 12.353 | 126 | NA | 0.24 |
| Total no of zoonoses | 342.651 | 27.6% | 34.412 | 470 | 26.8% | 0.23 |
Based on EFSA, BIOHAZ team and BIOCONTAM Unit 2013–2015 data and EU summary report on zoonoses, zoonotic agents; 2016 (10.2903/jefsa.2016.4634)
NA Not applicable
aWeighted arithmetic mean
Presentation of selected strains of Bacillus anthracis
| Allele size for MLVA—8 markers including virulence plasmids VNTR | Antibiotic susceptibility μg/ml | References | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Strain | Type | vrrA | vrrB1 | vrrB2 | vrrC1 | vrrC2 | CG3 | pXO1 | pXO2 | Amoxicillin with clavulanic acid | Fluoroquinolnes | Vancomycin | |
| JF3783-3788 | A | 314 | 229 | 162 | 535 | 604 | 158 | 135–138 | 139–141 | ≤ 2 | ≤ 0.25 | ≤1.0 | Pilo et al. ( |
| Chad 1–15 | Aβ | 290 | 229 | 171 | 616 | 604 | 158 | 123 | 133 | – | < 0.5 | – | Mohammed et al. ( |
| Gk13,35,44 | A1a | 313 | 265 | 190 | 380 | 210 | 380 | 270 | 180 | ≤ 0.03–1 | 0.06–0.25 | 0.5–4.0 | Ortatatli et al. ( |
| Gk27 | A1b | 301 | |||||||||||
| Govi-Altai | B | 10 | 16 | 7 | 53 | 17 | 2 | 8 | 11 | – | < 0.5 | – | Kruse et al. ( |
| GZBA1–32 | B | 2006–2011 | 313–349 | 229 | 581 | 513–542 | 168 | 132–138 | 143–149 | 0.016–0.5 | 0.032–0.094 | 0.75–5.0 | Coker et al. ( |
| ASC 32 | – | 313 | 229 | 162 | 613 | 604 | 153 | 129 | 139 | a | < 0.5 | ≤ 1.0 | Keim et al. ( |
Given are variable-number tandem repeats (VNTR) loci vrr -A, B1–2C1–2. CG3 and plasmids pX01–2. together with drug susceptibility to selected antibiotics
aβ-lactam resistance strains including ASC70 and 183; for more details see the text